Antiretroviral Therapy | Category | Clarifications/Special considerations |
---|---|---|
a) Nucleoside reverse transcriptase inhibitors (NRTIs) | Clarification: Antiretroviral drugs have the potential to either decrease or increase the levels of steroid hormones in women using hormonal contraceptives. Read More |
|
Abacavir (ABC) | 1 | |
Tenofovir (TDF) | 1 | |
Zidovudine (AZT) | 1 | |
Lamivudine (3TC) | 1 | |
Didanosine (DDI) | 1 | |
Emtricitabine (FTC) | 1 | |
Stavudine (D4T) | 1 | |
b) Non-nucleoside reverse transcriptase inhibitors (NNRTIs) | ||
Efavirenz (EFV) | ||
Etravirine (ETR) | DMPA=1 NET-EN=2 |
|
Nevirapine (NVP) | 1 | |
Rilpivirine (RPV) | DMPA=1 NET-EN=2 |
|
c) Protease inhibitors (PIs) | ||
Ritonavir-boosted atazanavir (ATV/r) | ||
Ritonavir-boosted lopinavir (LPV/r) | DMPA=1 NET-EN=2 |
|
Ritonavir-boosted darunavir (DRV/r) | DMPA=1 NET-EN=2 |
|
Ritonavir (RTV) | DMPA=1 NET-EN=2 |
|
d) Integrase inhibitors | ||
Raltegravir (RAL) | DMPA=1 NET-EN=2 |